A Phase 2, Randomized, Double-blind,Placebo-controlled Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy.
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2014
At a glance
- Drugs Belnacasan (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 14 Mar 2011 Status changed from active, no longer recruiting to completed.
- 21 Oct 2010 Planned end date changed from 1 Sep 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 21 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.